Convenient Home Access for Routine Monitoring in Diabetes (Charm-D Study)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorTameside General Hospital

About this trial

Diabetes mellitus is a global problem and regular monitoring of blood sugar control is important to reduce the risk of complications secondary to poor sugar control. To assess control a simple blood test is undertaken called the HbA1c. This test gives an assessment of the person's sugar control over the previous 3 months and needs to be done regularly so that changes can be made to their treatment. The HbA1c test is routinely performed in clinic and blood taken from a vein in the arm using a needle and syringe. This involves travelling to the clinic, taking time off work and expense to the patient. Many times and for the above reasons patients do not attend the clinic and therefore do not have the HbA1c performed. Therefore the clinician will not know how their diabetes is doing and also they will not be able to make changes to the patient's diabetes treatment.

In this study we would like to assess home monitoring of diabetes by doing the HbA1c at home and sent to the laboratory. At the same time we will be checking the patient's blood cholesterol (lipids) levels and thyroid function (to assess if the thyroid gland which is in the neck, is making adequate hormones).

In the study the patient will first visit the clinic where blood will be taken from the arm as is done in routine clinical care. Then the patient will take blood himself/herself either from the finger (finger prick as is done when a patient checks their own blood glucose) or from the upper arm using a device that will be applied to the skin and blood will be collected in a small tube attached to the device. Half the patients will be asked to do a finger prick test and the other half will do the upper arm skin blood draw. The patient will be asked to fill a questionnaire, this is to understand their experience with the blood self-collection and how they classify it in comparison with the routine clinical care.

The patient will then go home with the similar device that they used in the clinic and will be asked to do the same blood draw at home as they did in the clinic (either finger prick or upper arm blood draw). They will need to do this within 2 days of the visit to the clinic. They will then post the sample to the central laboratory in the envelope provided.

At the same time the patient will be asked to fill out a questionnaire. This is to understand the ease or difficulty of the testing at home but will also help us analyse the cost effectiveness of doing the home blood collection.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult subjects aged 18 years and over at the time of signing the informed consent

Ability to provide Informed consent

Type I and II diabetic patient

Ability to understand written and spoken English

Disqualifiers

Aged less than 18 years of age

Unable to provide informed consent

Unable to perform a blood draw at home

Trial population

Participants will be identified and approached during a routine diabetes clinic service run by Tameside and Glossop Integrated Care NHS Foundation Trust, based at Ashton Primary Care. This is a single site study. Consent, randomisation and a venous and a capillary self-collected sample will be collected at Tameside and Glossop Integrated Care NHS Foundation Trust. A second capillary sample will be self-collected by the participant in an outside the clinic setting and posted to the central laboratory. Participants will complete a questionnaire in the clinic as well as outside the clinic. The outside the clinic questionnaire will be posted back to the research team at Tameside General Hospital.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • HbA1c test

    Diagnostic test

    Patients will be asked to have a HbA1c test in the clinic with a venous draw and then either fingerprick or upper arm draw. They will do the latter again at home.

Treatment groups

300 Participants
are divided into 1 treatment group
Group A: Patients with type 1 and type 2 diabetes will be invited to take part in this study1 intervention

Trial outcomes

Primary outcomes

1

HbA1c

to evaluate the accuracy and compare HbA1c measurement in-clinic testing by venous draw by health professionals vs home-based self-collected capillary blood sampling

Time frame
12 months

Secondary outcomes

1

Lipids

to evaluate the accuracy and compare lipid measurement in-clinic testing by venous draw by health professionals vs home-based self-collected capillary blood sampling

Time frame
12 months
2

Thyroid function

to evaluate the accuracy and compare thyroid function measurement in-clinic testing by venous draw by health professionals vs home-based self-collected capillary blood sampling

Time frame
12 months
3

Participant acceptance

Participant acceptability of collecting a outside the clinic capillary sample. Patients will be asked to answer questions on pain experience from venous draw vs home collection of blood sample, convenience of attending clinic for venous drwa vs home- collection and will be scored from 1-10 (Visual analo scale).

Time frame
12 months
4

Health economics

Health economic value of collecting outside the clinic capillary sample versus standard of care venous draw

Time frame
12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Tameside General Hospital

Lead sponsor

Roche Diagnostic Ltd.

Collaborator